Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Transplant Cell Ther. 2023 Jun;29(6):387.e1-387.e7. doi: 10.1016/j.jtct.2023.03.017. Epub 2023 Mar 22.
With advances in therapies for hematologic cancers, older adults increasingly undergo hematopoietic stem cell transplantation (HSCT). Older adults may potentially experience an exaggerated burden of toxicity from HSCT. Studies examining the quality of life (QOL), physical functioning, and psychological symptom trajectory for older adults undergoing HSCT are limited. Our primary aim was to describe the trajectory of QOL, physical functioning, and psychological distress of older adults undergoing HSCT. Secondarily, we aimed to compare the trajectory of QOL, physical functioning, and psychological distress of older and younger adults undergoing HSCT and to evaluate factors associated with QOL trajectory in older adults undergoing HSCT. We conducted secondary analyses of two prospective studies conducted at Massachusetts General Hospital. From 2011 to 2016, we enrolled 250 adults undergoing allogeneic or autologous HSCT. Older age was defined as age ≥65 years. We collected patient-reported outcomes (PROs) within 72 hours of admission for HSCT, at hematologic nadir (2 weeks), and at 6 months after HSCT. To assess QOL, physical functioning, and psychological symptoms, we used the Functional Assessment of Cancer Therapy (FACT)-Bone Marrow Transplant, FACT-Trial Outcome Index, and Patient Health Questionnaire-9, respectively. We used the post-traumatic stress disorder (PTSD) Checklist-Civilian Version to assess PTSD symptoms. We fit linear mixed effects models to characterize trajectories of changes in PROs across timepoints and to evaluate baseline factors associated with QOL trajectories in older adults. Overall 30.4% (76/250) of our cohort was 65 years or older. All older adults undergoing allogeneic HSCT received a reduced intensity conditioning regimen. At 2 weeks after HSCT, older patients experienced a decline in QOL (Δ = -16.6, P < .001), physical functioning (Δ = -15.4, P < .001) and an increase in depression symptoms (Δ = 3.8, P < .001). At 6 months after HSCT, QOL (Δ = 1.4, P = .7), physical functioning (Δ = 1.7, P = .5), and depression symptoms (Δ = 0.4, P = .6) recovered to baseline values. At 6 months after HSCT, the proportion of older patients with PTSD symptoms increased from 5.3% (4/76) at baseline to 13.2% (10/76). There was no significant difference in slopes or trajectories of PROs between older and younger patients. In older adults, baseline psychological distress was associated with significantly worse QOL trajectory (Δ= -21.6, P ≤ .001). Older adults experienced a sharp decline in QOL and physical functioning and an increase in depression symptoms within 2 weeks of HSCT hospitalization. Baseline psychological distress was associated with a pronounced worsening in post-HSCT QOL trajectory. These findings underscore the need for supportive care interventions to improve the experience of older adults undergoing HSCT.
随着血液系统恶性肿瘤治疗方法的进步,越来越多的老年人接受造血干细胞移植(HSCT)。老年人可能会因 HSCT 而经历毒性负担的增加。目前,研究人员对正在接受 HSCT 的老年人的生活质量(QOL)、身体功能和心理症状轨迹的研究有限。我们的主要目的是描述正在接受 HSCT 的老年人的 QOL、身体功能和心理困扰的轨迹。其次,我们旨在比较正在接受 HSCT 的老年和年轻患者的 QOL、身体功能和心理困扰的轨迹,并评估与正在接受 HSCT 的老年患者 QOL 轨迹相关的因素。我们对在马萨诸塞州总医院进行的两项前瞻性研究进行了二次分析。2011 年至 2016 年,我们纳入了 250 名接受同种异体或自体 HSCT 的成年人。年龄较大定义为年龄≥65 岁。我们在 HSCT 入院后 72 小时内、血液学最低点(2 周)和 HSCT 后 6 个月采集患者报告的结局(PRO)。为了评估 QOL、身体功能和心理症状,我们分别使用功能性评估癌症治疗量表(FACT)-骨髓移植、FACT-临床试验结局指数和患者健康问卷-9。我们使用创伤后应激障碍(PTSD)检查表-平民版来评估 PTSD 症状。我们使用线性混合效应模型来描述 PRO 在各时间点的变化轨迹,并评估与老年患者 QOL 轨迹相关的基线因素。我们队列中共有 30.4%(76/250)的患者年龄在 65 岁或以上。所有接受同种异体 HSCT 的老年患者均接受了强度降低的预处理方案。在 HSCT 后 2 周,老年患者的 QOL(Δ= -16.6,P <.001)、身体功能(Δ= -15.4,P <.001)和抑郁症状(Δ= 3.8,P <.001)均下降。在 HSCT 后 6 个月,QOL(Δ= 1.4,P =.7)、身体功能(Δ= 1.7,P =.5)和抑郁症状(Δ= 0.4,P =.6)恢复到基线值。在 HSCT 后 6 个月,老年患者 PTSD 症状的比例从基线时的 5.3%(4/76)增加到 13.2%(10/76)。老年患者和年轻患者的 PRO 斜率或轨迹无显著差异。在老年患者中,基线时的心理困扰与 QOL 轨迹显著恶化相关(Δ= -21.6,P ≤.001)。老年患者在 HSCT 住院期间的 2 周内 QOL 和身体功能急剧下降,抑郁症状增加。基线时的心理困扰与 HSCT 后 QOL 轨迹的明显恶化有关。这些发现强调需要进行支持性护理干预,以改善正在接受 HSCT 的老年患者的体验。